title: Rapid chemiluminescent sandwich enzyme immunoassay capable of consecutively quantifying multiple tumor markers in a sample.
abstract: Using the role of p-iodophenol in enzyme assay, enhanced 1,1'-oxalyldiimidazole chemiluminescent enzyme immunoassays (ODI-CLEIAs) were developed to consecutively quantify trace levels of triple tumor markers, such as alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), and prostate specific antigen (PSA) in a sample. Due to the high sensitivity of enhanced ODI-CLEIAs, it was possible to fix the incubation times (1) to capture a tumor marker with two antibodies, which are primary antibody immobilized on the surface of polystyrene strip-well and detection antibody-conjugated horseradish peroxidase (HRP), and (2) to form resorufin with the addition of substrates (e.g., Amplex Red, H2O2) in order to quantify triple markers in human serum. Enhanced ODI-CLEIAs capable of consecutively and rapidly quantifying triple markers with the same incubation time were more sensitive than conventional enzyme-linked immunosorbent assay (ELISA) capable of separately and slowly quantifying them with different incubation times. In addition, accuracy, precision, and recovery of enhanced ODI CLEIAs in the presence of p-iodophenol were acceptable within statistical error range.
authors.affiliation: Luminescent MD, LLC, Hagerstown, MD 21742, USA; Thomas Jefferson High School for Science and Technology, Alexandria, VA 22312, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Kim
authors.affiliation: Luminescent MD, LLC, Hagerstown, MD 21742, USA; Langley High School, McLean, VA 22101, USA.
authors.forename: Jennie
authors.initials: J
authors.lastname: Kim
authors.affiliation: Luminescent MD, LLC, Hagerstown, MD 21742, USA.
authors.forename: Tae Ho D
authors.initials: TH
authors.lastname: Rho
authors.affiliation: Luminescent MD, LLC, Hagerstown, MD 21742, USA. Electronic address: jhlee@luminescentmd.com.
authors.forename: Ji Hoon
authors.initials: JH
authors.lastname: Lee
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002138:Calibration; D002272:Carcinoembryonic Antigen / Q000097:blood; D006735:Horseradish Peroxidase / Q000737:chemistry; D006801:Humans; D006861:Hydrogen Peroxide / Q000737:chemistry; D007124:Immunoenzyme Techniques / Q000379:methods*; D007462:Iodobenzenes / Q000737:chemistry*; D049449:Luminescence; D008163:Luminescent Measurements; D010078:Oxazines / Q000737:chemistry; D017430:Prostate-Specific Antigen / Q000097:blood; D015203:Reproducibility of Results; D000509:alpha-Fetoproteins / Q000737:chemistry
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D007462:Iodobenzenes; D010078:Oxazines; D000509:alpha-Fetoproteins; C470430:Amplex Red; C050181:4-iodophenol; C014180:resorufin; D006861:Hydrogen Peroxide; D006735:Horseradish Peroxidase; D017430:Prostate-Specific Antigen
keywords: 1,1′-oxalyldiimidazole (ODI) chemiluminescence; Chemiluminescent enzyme immunoassays; Enhanced chemiluminescence; Tumor markers; p-iodophenol